Compelling Efficacy and Safety Data for Orsiro Hybrid Drug-Eluting Stent Presented during EuroPCR Hotline Session
ORIENT Trial Establishes Orsiro's Non-Inferiority to Resolute Integrity Stent, while a STEMI Subgroup from the BIOSCIENCE Trial Has 50 Percent Lower TLF Rate vs. Competitor XienceBUELACH, Switzerland, )
“Orsiro’s refined design, including a biodegradable polymer and ultrathin struts, improve patient safety and angiographic outcomes,” commented ORIENT trial principal investigator Dr. Tae-Jin Youn, Seoul National University Bundang Hospital, South Korea. “In this trial, Orsiro conclusively demonstrated non-inferiority to the competitor DES in terms of in-stent late lumen loss.”
The ORIENT trial’s primary endpoint was in-stent late lumen loss (LLL) at nine months, an angiographic endpoint. Orsiro demonstrated significant non-inferiority for the primary end point—at nine months the trial’s Orsiro arm had an average LLL of 0.10 ± 0.35, while patients in the Resolute Integrity arm had an LLL of 0.16 ± 0.39 (P for non-inferiority=<0.001). The trial furthermore highlighted Orsiro’s excellent safety profile, with no stent thrombosis observed.
At EuroPCR 2016, positive 24 months results for ST-segment elevation myocardial infarction (STEMI) patients were also presented as part of the official program and during a scientific symposium on Orsiro. STEMI is a potentially fatal type of heart attack caused by a prolonged obstruction of blood supply in the heart. Every year nearly 250,000 people experience STEMI heart attacks. A subanalysis of 407 STEMI patients was included in the multicenter, randomized, controlled non-inferiority BIOSCIENCE trial. Results from the trial have been published in The Lancet and EuroIntervention; these had already revealed that Orsiro might be associated with better clinical outcomes than Xience Prime/Xpedition for this indication.
At two years, BIOSCIENCE’s primary endpoint of target lesion failure (TLF) occurred in 5.4 percent of STEMI patients treated with Orsiro compared with 10.8 percent of those treated with Xience Prime/Xpedition. BIOSCIENCE is the largest investigator-initiated study to date evaluating the safety and efficacy of Orsiro, a bioabsorbable polymer DES, in comparison to the durable polymer Xience Prime/Xpedition DES.
“Orsiro continues to prove itself against established competitors in a variety of indications,” stated Dr. Alexander Uhl, Vice President Marketing, BIOTRONIK Vascular Intervention. “As our robust clinical program continues to drive clinical acceptance worldwide, Orsiro has already benefited half a million of patients.”
The Orsiro Hybrid Drug-Eluting Stent (DES), launched in 2011, features the latest development in BIOTRONIK stent technology – a unique hybrid solution that combines passive and active components. proBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and the surrounding tissue. BIOlute active coating contains a highly biocompatible polymer that delivers a limus drug via a bioabsorbable matrix. This hybrid coating is layered on top of the high performance PRO-Kinetic Energy stent platform, renowned for its advanced ultrathin-strut stent design and outstanding deliverability.